Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 717480 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
ElectronicAdd to Basket



Global Generics Guide 2nd Edition: Optimizing Geographical and Strategic Positioning in an Evolving Generics Landscape
Datamonitor, Nov 2003, Pages: 366


  Description  
  Table of Contents  
    
    
    
   
 Enquire before Buying  
 Send to a Friend  

Introduction

The global generics market is changing. A favorable environment in the US has lead to intense competition in commodity generics, and left players seeking alternative options to drive further growth. Meanwhile, regulatory reform in under penetrated EU generics markets is boosting generic usage, attracting attention from overseas players, and bringing with it its own set of challenges.

Scope

Benchmarking of leading generics players by 2002 sales, market share and financial position and by forecast ethical sales between 2003 and 2008

Analysis of portfolio management and geographic expansion strategies specific to US and EU based players

Full profiles of 11 leading generics players - Alpharma, Andrx, Barr, Biovail, IVAX, Mylan, Ranbaxy, SICOR, Stada, Teva, Watson

Report Highlights

The global generics market is forecast strong growth between 2003 and 2008. In the US, patent expiries will be the key driver, with $84 billion worth of 2002 blockbusters being at risk of generic competition by 2008. Europe is expected to outperform the US in terms of rate of growth in generics sales, with increased generic usage the key driver.

Despite the introduction of cost containment measures resulting in price cuts in mature generics markets such as the UK and Germany, the net benefit of regulatory reform and cost containment measures will be positive for the European generics industry, particularly in those markets where generic penetration is currently very low.

In 2008, the best positioned generics companies will be those that have technology platforms enabling them to maintain margins in face of increased competition, and that have international manufacturing and distribution networks that allow them to profit from the growth potential in southern European markets.

Reasons to Purchase

Understand the drivers of growth in the major generics markets, and tailor your portfolio management strategy to maximize profit return

Benchmark your strategy against key rivals in the generics sector

Assess the impact of regulatory reform and increased generic penetration on the branded sector




Customers who bought this item also bought

Pharmavitae Generics - Teva

Mylan: PharmaVitae Generics Profile

Generics Series: Generics Trends in the Seven Major Markets and Beyond

Global Generics Guide 3rd Edition: Benchmarking Generics Company Capabilities and Strategy

Global Generics Guide: Capitalizing On an $82 Billion Opportunity

Global Generics Industry Report

Growth Strategies In Generics: Innovative And Aggressive Strategies And Their Impact On Branded Pharmaceuticals

Global Generics Guide: Benchmarking the Key Players

Teva Pharmaceutical Industries Generics Company Intelligence Report

Generics: Global Industry Guide

Watson: PharmaVitae Generics Profile

Barr: PharmaVitae Generics Profile



Top of page


   All rights reserved. � Copyright 2009 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds